VYNE Therapeutics's market cap is currently ―. The company's EPS TTM is $-7.001; its P/E ratio is -0.33; VYNE Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.24. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 76.00K	$ 114.00K	$ 135.00K	$ 99.00K	$ 6.00K
Gross Profit	$ 52.00K	$ 114.00K	$ 135.00K	$ 99.00K	$ 6.00K
EBIT	$ -6.11M	$ -6.07M	$ -10.04M	$ -5.61M	$ -7.75M
EBITDA	$ -5.99M	$ -6.07M	$ -10.04M	$ -5.61M	$ -7.88M
Net Income Common Stockholders	$ -6.19M	$ -6.58M	$ -10.04M	$ -5.61M	$ -7.76M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 93.25M	$ 15.45M	$ 20.63M	$ 30.28M	$ 31.01M
Total Assets	$ 97.69M	$ 19.27M	$ 24.96M	$ 35.26M	$ 40.76M
Total Debt	$ 214.00K	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -93.04M	$ -15.45M	$ -20.63M	$ -30.28M	$ -31.01M
Total Liabilities	$ 8.95M	$ 7.76M	$ 7.69M	$ 8.82M	$ 9.35M
Stockholders Equity	$ 88.73M	$ 11.51M	$ 17.27M	$ 26.44M	$ 31.20M
Cash Flow	-
Free Cash Flow	$ -5.14M	$ -5.10M	$ -9.60M	$ -5.39M	$ -3.90M
Operating Cash Flow	$ -5.14M	$ -5.10M	$ -9.60M	$ -5.39M	$ -3.90M
Investing Cash Flow	$ -62.35M	-	-	$ 5.00M	$ -935.00K
Financing Cash Flow	$ 82.66M	$ -47.00K	$ -5.00K	$ -217.00K	$ 208.00K

Currency in USD

VYNE Therapeutics Earnings and Revenue History

Income Statement >

VYNE Therapeutics Debt to Assets

Balance Sheet >

VYNE Therapeutics Cash Flow

Cash Flow >

VYNE Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing